SCHEMBL4172399

SCHEMBL4172399

CCCn1c(=O)c2c(nc(Cc3ccccc3)n2CCNCC(O)CC)n(CCc2cccc(NC(=O)C(CC(=O)O)NC(=O)CCCCCN3C(=O)C=CC3=O)c2)c1=O

nearest known ligand 0.35

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.34
ADORA2B P29275 1/20 0.34
MAPT P10636 3/20 0.34
TP53 P04637 1/20 0.34
TSHR P16473 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.32
CASP1 P29466 2/20 0.32
ALDH1A1 P00352 1/20 0.32
KMT2A Q03164 1/20 0.32
SIRT2 Q8IXJ6 1/20 0.31
SIRT1 Q96EB6 1/20 0.31
SIRT3 Q9NTG7 1/20 0.31
THRB P10828 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4172607 0.95 MAPT (0.34) ADORA2AADORA2BMAPTTP53TSHR
SCHEMBL4182480 0.94 ADORA2A (0.35) ADORA2AADORA2BMAPTTP53TSHR
SCHEMBL4186574 0.93 ADORA2A (0.35) ADORA2AADORA2BMAPTTP53TSHR
SCHEMBL4189331 0.93 ADORA2A (0.35) ADORA2AADORA2BMAPTTP53TSHR
SCHEMBL4172006 0.92 TSHR (0.34) ADORA2AADORA2BTSHRSMN1; SMN2CASP1
SCHEMBL4172631 0.92 ADORA2A (0.35) ADORA2AADORA2BMAPTTP53TSHR
SCHEMBL4173940 0.89 MAPT (0.36) ADORA2AADORA2BMAPTTP53TSHR
SCHEMBL4165128 0.88 CHRNB2 (0.36) ADORA2AADORA2BMAPTTP53TSHR
SCHEMBL4169360 0.88 ADORA2B (0.35) ADORA2AADORA2BMAPTTP53TSHR
SCHEMBL4180241 0.87 CHRNB2 (0.36) ADORA2AADORA2BMAPTTP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090068101-A9 A1 Adenosine Receptor Antagonists ENDACEA, INC. (US) 2009-03-12 US disclosed
US-20070274910-A1 e.g. 3-[2-(2-Aminophenyl)ethyl]-8-benzyl-7-(2-methylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility ENDACEA, INC. (US) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070274910-A1 e.g. 3-[2-(2-Aminophenyl)ethyl]-8-benzyl-7-(2-methylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility HRH3, HRH1, HRH2 ADORA2A 7/4885ADORA2B 9/4885MAPT 4646/4885
US-20090068101-A9 A1 Adenosine Receptor Antagonists ADORA1, ADORA3, ADORA2A ADORA2A 3/4885ADORA2B 4/4885MAPT 4543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.